EUVIMEDEUVIMED entdecken
Crossref

The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma

Hamish Innes, Victoria Hamill, Sharon Hutchinson, Felix Stickel, Jochen Hampe, Marsha Y. Morgan, Stephan Buch

Zeitschrift für Gastroenterologie · 01.01.2023 · 61 (01) · e23

DOI: 10.1055/s-0042-1759967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.01.2023. Verfasst von Hamish Innes und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The genetic factors associated with survival following diagnosis of hepatocellular carcinoma (HCC) are not well understood. The goal of this study was to assess if polymorphisms influencing susceptibility to HCC are also associated with HCC prognosis.

Methods

United Kingdom Biobank participants diagnosed with HCC after study enrolment were included. The primary outcome event was all-cause mortality. Patients were followed from the date of HCC diagnosis to death or the registry completion date. Five HCC susceptibility polymorphisms were considered: rs738409 (PNPLA3), rs58542926 (TM6SF2); rs72613567 (HSD17B13); rs2242652 (TERT) and rs708113 (WNT3A). Cox regression was used to determine the independent association between these genetic loci and HCC mortality risk. All models included adjustment for age at HCC diagnosis, gender, ethnicity, receipt of curative HCC treatment, severity of underlying liver disease, and liver disease aetiology. Sensitivity analyses were performed using liver-related mortality and HCC mortality as alternative outcome events.

Results

The final sample included 439 patients with an average of 1.9 years follow-up per patient. There were 321,295 and 235 all-cause, liver-related and HCC-related deaths. The 3-year all-cause mortality proportion was: 68.8% (95%CI: 64.1-73.3). In multivariate analysis, rs72613567:TA (HSD17B13) was the only genetic susceptibility variant associated with liver-related mortality (aHR:0.76; 95%CI:0.62-0.92; P=0.005). Other factors associated were Baveno stage 3/4 (aHR:1.65; 95%CI:1.06-2.59; P=0.03) and HCC treatment with curative intent (aHR:0.25; 95%CI: 0.17-0.37; P

Zitieren

APA

Innes, H., Hamill, V., Hutchinson, S., Stickel, F., Hampe, J., Morgan, M. Y., & Buch, S. (2023). The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. Zeitschrift für Gastroenterologie, 61(01), e23. https://doi.org/10.1055/s-0042-1759967

Vancouver

Innes H, Hamill V, Hutchinson S, Stickel F, Hampe J, Morgan MY, et al. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma. Zeitschrift für Gastroenterologie. 2023;61(01):e23. doi:10.1055/s-0042-1759967

BibTeX
@article{Innes2023,
  author = {Innes, Hamish and Hamill, Victoria and Hutchinson, Sharon and Stickel, Felix and Hampe, Jochen and Morgan, Marsha Y. and Buch, Stephan},
  title = {The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2023},
  volume = {61},
  number = {01},
  pages = {e23},
  doi = {10.1055/s-0042-1759967}
}
Kostenlos starten →